Technologieangebote

The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).

The invention discloses an improved version of the chorionallantic membrane, for accurate quantification of metastatic cells in different organs of the chicken embryo at a high sensitivity.

The invention identifies new mutations in the TERT promoter which qualify as diagnostic and prognostic marker.

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.

Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.